Adverum Biotechnologies, Inc.
ADVM
$4.19
$0.020.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -0.64% | 117.14% | 86.55% | 59.70% | -94.76% |
| Gross Profit | -1,154.65% | -117.14% | -86.55% | -59.70% | 99.59% |
| SG&A Expenses | -39.26% | -19.47% | 41.23% | 137.95% | 8.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.51% | 51.52% | 65.15% | 100.00% | 2.63% |
| Operating Income | -39.45% | -51.52% | -65.15% | -100.00% | 0.26% |
| Income Before Tax | -47.30% | -61.29% | -73.20% | -103.13% | 1.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.30% | -61.29% | -73.20% | -111.16% | 1.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.30% | -61.29% | -73.20% | -111.16% | 1.62% |
| EBIT | -39.45% | -51.52% | -65.15% | -100.00% | 0.26% |
| EBITDA | -41.76% | -54.38% | -68.56% | -104.01% | -1.60% |
| EPS Basic | -30.92% | -60.08% | -36.31% | -2.27% | 52.40% |
| Normalized Basic EPS | -30.92% | -60.08% | -36.32% | 1.62% | 52.38% |
| EPS Diluted | -30.92% | -60.08% | -36.31% | -2.27% | 52.40% |
| Normalized Diluted EPS | -30.92% | -60.08% | -36.32% | 1.62% | 52.38% |
| Average Basic Shares Outstanding | 12.51% | 0.76% | 27.06% | 106.48% | 106.69% |
| Average Diluted Shares Outstanding | 12.51% | 0.76% | 27.06% | 106.48% | 106.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |